MADRIGAL PHARMACEUTICA

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

14 Mar 2024 15:15:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

05 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer

28 Feb 2024 06:01:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

28 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

21 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

08 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Additions to Its Leadership Team

29 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

22 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference

04 Jan 2024 07:00:01 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 15:30:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

22 Dec 2023 15:30:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

27 Nov 2023 15:30:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer

21 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

15 Nov 2023 15:45:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health

10 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

10 Nov 2023 06:30:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results

06 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

02 Nov 2023 15:05:00 By Nasdaq GlobeNewswire